Sun Yat-sen University Cancer Center

Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting

Retrieved on: 
Tuesday, September 5, 2023
Abstract (summary), GBM, Neuro-Oncology (journal), Sun, Glioblastoma, Harvard Medical School, Professor, Patient, UCSF, SAN, Annual general meeting, Poster, European Association of Urology, Sun Yat-sen University Cancer Center, Therapy, UCSF Medical Center, Pharmaceutical industry, Radiation therapy

SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023.

Key Points: 
  • SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023.
  • The presentation will include data from its lead program, VAL-083, for the treatment of recurrent glioblastoma.
  • Kintara recently hosted an event featuring key opinion leaders Patrick Y. Wen, M.D.
  • (UCSF Health) discussing the current treatment landscape for patients suffering from GBM along with Kintara's potential treatment solution with VAL-083.

Live from ASCO 2023 | Ascentage Pharma Releases Updated Data Showing APG-2449's Potential as a New Treatment for Drug-Resistant NSCLC

Retrieved on: 
Tuesday, June 6, 2023
PRS, PD, Diarrhea, Cohort, American Society of Clinical Oncology, DCR, Cancer, Trae tha Truth, Pharmacokinetics, Sun, TKI, CHB, NSCLC, Lung cancer, Sun Yat-sen University Cancer Center, Female, ASCO, Vomiting, ORR, Drug resistance, Patient, Annual general meeting, Nausea, ALT, FAK, Poster, Principal, Notifiable disease, AST, Society, Landing slot, SD, Hepatitis, PR, Safety, ALK, Pharmaceutical industry

Among these results, the updated clinical data of APG-2449 showed the potential as a new treatment option that can effectively overcome drug resistance through the targeted inhibition of FAK.

Key Points: 
  • Among these results, the updated clinical data of APG-2449 showed the potential as a new treatment option that can effectively overcome drug resistance through the targeted inhibition of FAK.
  • Developed by Ascentage Pharma, APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development.
  • "We believe that FAK inhibition could be a new treatment strategy for patients with NSCLC resistant to second-generation ALK inhibitors."
  • Appendix: The four posters on Ascentage Pharma's four lead drug candidates, including APG-2449, presented at this year's ASCO Annual Meeting.

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

Retrieved on: 
Friday, May 12, 2023
Carcinoma, Human, Index, Ira Pastan, PD, JHO, Half-life, Hematology, Neoplasm, CI, Sun, Trae tha Truth, Pharmacokinetics, Lung cancer, NSCLC, Immunotherapy, Hypothyroidism, Sun Yat-sen University Cancer Center, Rash, Nasopharyngeal carcinoma, Incidence, Journal, Dor, Cervical cancer, Patient, Phases of clinical research, Itch, MTD, NPC, PD-1, ORR, Safety, Pharmaceutical industry, Vaccine, Medical imaging

JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol.

Key Points: 
  • JINAN, China, May 12, 2023 /PRNewswire/ -- On May 8, 2023, Journal of Hematology & Oncology (JHO, 2022 impact factor of 23.168) published the results of the Phase I clinical study of Qilu Pharma's immunotherapy bifunctional antibody, QL1706 (J Hematol Oncol.
  • The results provide further support for the use of dual immunotherapy in patients with advanced solid tumors.
  • The CTLA-4 antibody has a shorter elimination half-life in vivo, with a shorter exposure for CTLA-4 antibodies in a dosing cycle.
  • This study provides strong support for further clinical research of QL1706, which is expected to become a new approach of dual immunotherapy.

Alpha Tau Announces the Publication of its US Multicenter Pilot Skin Cancer Trial Results in JAMA Network Open

Retrieved on: 
Thursday, May 11, 2023
Restart, CT, Alpha Sigma Tau, Alpha, Symantec Endpoint Protection, Sun Yat-sen University Cancer Center, Safety, Skin cancer, Skin, Quality of life, Toxicity, Radiation therapy, Dart, MD, JAMA Network Open, Patient, Carcinoma, Memorial Sloan Kettering Cancer Center, Clinical research, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging

JERUSALEM, May 11, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the publication of the results of its US multicenter pilot trial in JAMA Network Open.

Key Points: 
  • JERUSALEM, May 11, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the publication of the results of its US multicenter pilot trial in JAMA Network Open.
  • The pilot study was designed to evaluate the feasibility of Alpha DaRT in treating ten subjects with malignant skin and superficial soft tissue tumors.
  • Alpha Tau CEO Uzi Sofer commented, “The publication of the pilot trial results in JAMA Network Open is a moment of great pride for all of us at Alpha Tau.
  • Given the promising results of this pilot trial, we look forward to the results of the pivotal ReSTART trial.”

Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology

Retrieved on: 
Thursday, May 11, 2023
Carcinoma, Human, Index, Ira Pastan, PD, JHO, Half-life, Hematology, Neoplasm, CI, Sun, Trae tha Truth, Pharmacokinetics, Lung cancer, Toxicity, Multimedia, NSCLC, Immunotherapy, Hypothyroidism, Sun Yat-sen University Cancer Center, Rash, Nasopharyngeal carcinoma, Incidence, Journal, Dor, Cervical cancer, Patient, Immunoglobulin G, Phases of clinical research, Itch, MTD, NPC, PD-1, ORR, Safety, Pharmaceutical industry, Medical imaging

The results provide further support for the use of dual immunotherapy in patients with advanced solid tumors.

Key Points: 
  • The results provide further support for the use of dual immunotherapy in patients with advanced solid tumors.
  • The CTLA-4 antibody has a shorter elimination half-life in vivo, with a shorter exposure for CTLA-4 antibodies in a dosing cycle.
  • QL1706 therefore not only has a synergistic mechanism to block PD-1 and CTLA-4, but also reduces the toxicity of CTLA-4 antibodies.
  • First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.

University Cancer & Blood Center announces opening date of state-of-the art Comprehensive Cancer Treatment Center

Retrieved on: 
Tuesday, May 2, 2023
Oncology, UCBC, NCI-designated Cancer Center, Patient, Radiation, Surgical oncology, Sun Yat-sen University Cancer Center, NCI, Gastroenterology, UCSF Helen Diller Family Comprehensive Cancer Center, Clinical research, Palliative care, Nursing

ATHENS, Ga., May 2, 2023 /PRNewswire/ -- University Cancer & Blood Center (UCBC) will open its Comprehensive Cancer Center in August, offering a fully integrated approach to cancer care with incomparable, convenient access. This will be the first community cancer center of its kind in the region.

Key Points: 
  • ATHENS, Ga., May 2, 2023 /PRNewswire/ -- University Cancer & Blood Center (UCBC) will open its Comprehensive Cancer Center in August, offering a fully integrated approach to cancer care with incomparable, convenient access.
  • This will be the first community cancer center of its kind in the region.
  • "The UCBC Comprehensive Cancer Center offers the full spectrum of cancer care delivery," says Dr. Petros Nikolinakos, Managing Partner and Director of Clinical Research at UCBC.
  • Learn more about UCBC's Comprehensive Cancer Center: 706-353-2990, universitycancer.com.

CancerVAX Lands Byron Elton

Retrieved on: 
Monday, April 3, 2023
Carbon, Online, Canada, AOL, Carbon Sciences, Senior, Marketing, E-commerce, Cancer, CancerVax, Television, AGM, Marketing communications, CMO, CBS, Brigham Young University, Organization, Physician, Advertising, ABC, Region, UCLA, Sun Yat-sen University Cancer Center, Social media, Pharmaceutical industry, Management, LEHI

Since June 2018, he has been President of Elton Enterprises, Inc., which is involved in the wellness, fitness and health sector.

Key Points: 
  • Since June 2018, he has been President of Elton Enterprises, Inc., which is involved in the wellness, fitness and health sector.
  • Mr. Elton previously served as Senior Vice President of Sales for Univision Online from 2007 to 2008.
  • “Adding Byron Elton to the Company’s management team must be considered a major coup,” said Ryan Davies, CancerVax CEO.
  • Working with the CancerVax and UCLA teams is a very exciting opportunity.”
    For more information about CancerVAX, please visit our website at https://cancervax.com

Junshi Biosciences Announces 2022 Full Year Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, March 31, 2023
DSM-IV codes, Bevacizumab, COVID-19, Shanghai Stock Exchange, Star Market, European Medicines Agency, XPO1, Ankylosing spondylitis, Patent, Patient, EGFR, ESCC, NPC, R, Spacecraft, FGFR2, Fasting, ATR, Rheumatoid arthritis, Sun, Platinum, Bamlanivimab/etesevimab, Infection, Research, Sun Yat-sen University Cancer Center, SSE, Anaplastic lymphoma kinase, Uveitis, IDH1, Phase, FDA, Pemetrexed, IND, NMPA, Total, CGMP, CD3, Adalimumab, Cancer, Psoriasis, Wujiang, HKEX, Disease, Synergist, PARP, RMB, The New England Journal of Medicine, Acceleration, Nature, Paclitaxel, Targeted therapy, Cisplatin, Respiratory syncytial virus, SHP2, NEJM, Signal transduction, Pharmaceutical industry, Video game, Fine chemical, Vaccine, Medical device

SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.

Key Points: 
  • SHANGHAI, China, March 31, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced financial results for the 2022 full year and provided corporate updates.
  • Total research and development (“R&D”) expenses were approximately RMB 2,384 million in 2022, representing an increase of approximately 15% compared to 2021.
  • Loss attributable to the owners of the company was RMB 2,386 million in 2022, representing an increase of RMB 1,667 million compared to 2021.
  • In May 2022, the IND application for JS105, a PI3K-α inhibitor jointly developed by Risen (Suzhou) Biosciences Co., Ltd. (“Risen Biosciences”) and the company, was approved by the NMPA.

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Retrieved on: 
Thursday, March 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Genetics, CRISPR, Seamless, DNA, Drug discovery, Gene editing, Therapy, Biology, Entrepreneurship, Faculty, Recombinase, Genome, Enzyme, Wellington Partners, EU, Sun Yat-sen University Cancer Center, University of Alberta Faculty of Medicine and Dentistry, Technische Universität Darmstadt, BMBF, Disease, Philosophy, Doctor of Philosophy, Molecular biology, Pharmaceutical industry, Antibiotics, Medicine

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform the treatment of severe diseases.

Key Points: 
  • Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform the treatment of severe diseases.
  • We believe our pioneering technology will allow us to shatter the boundaries that exist in gene editing methods today,” said Anne-K. Heninger, PhD, Co-Founder and Chief Executive Officer of Seamless Therapeutics.
  • Seamless Therapeutics has a first-mover position with its innovative platform capable of modifying the long held standard recombination technology into a universal gene editing tool with unprecedented specificity.
  • We are excited to support Seamless Therapeutics in its pursuit of taking a leadership position in the rapidly evolving gene editing arena,” added Karl Nägler, PhD, Managing Partner at Wellington Partners.

Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

Retrieved on: 
Wednesday, March 8, 2023
Observation, Alpha, Sun Yat-sen University Cancer Center, Hospital, Progression-free survival, Recurrence, Quality of life, Safety, Carcinoma, Patient, Restart, Hope, Breakthrough, Alpha Sigma Tau, FDA, Pharmaceutical industry, Medical imaging

JERUSALEM, March 08, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”)  (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced that the first two patients were enrolled and treated today in its pivotal multicenter trial, known as the ReSTART trial (Recurrent SCC Treatment with Alpha DaRT Radiation Therapy), for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC). The patients were treated at the University Cancer Center in Houston, Texas.

Key Points: 
  • The primary study endpoints include overall objective response rate, based on best overall response, duration of response at 6-months from initial observation of a response to Alpha DaRT insertion, and safety of the Alpha DaRT treatment.
  • The study’s secondary objectives are to assess the progression-free survival and overall survival at 1-year following Alpha DaRT treatment, overall duration of response, local control, and quality of life.
  • Dr. Mark A. D’Andrea, radiation oncologist at University Cancer Center in Houston, commented, “I believe that Alpha DaRT can be a real breakthrough in the treatment of recurrent cSCC.
  • These patients have exhausted the effective treatment options available to them, and Alpha DaRT may give these patients additional hope for a successful outcome.